Published in Epilepsy Behav on March 22, 2013
A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging (1998) 23.54
Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol (1998) 5.47
Tuberous sclerosis. Lancet (2008) 4.24
A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci (2007) 3.51
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet (2000) 3.44
Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med (1998) 3.16
Epidemiology of tuberous sclerosis. Ann N Y Acad Sci (1991) 2.96
Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol (2008) 2.74
Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med (1993) 2.59
1H metabolite relaxation times at 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional differences in transverse relaxation. J Magn Reson Imaging (2004) 2.47
Magnetic resonance spectroscopy of the human brain. Anat Rec (2001) 2.18
Diagnosis of tuberous sclerosis complex. J Child Neurol (2004) 2.11
Comparison of longitudinal metabolite relaxation times in different regions of the human brain at 1.5 and 3 Tesla. Magn Reson Med (2003) 1.72
Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology (2007) 1.64
Proton echo-planar spectroscopic imaging of J-coupled resonances in human brain at 3 and 4 Tesla. Magn Reson Med (2007) 1.53
Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med (1989) 1.43
Fully automatic segmentation of the brain from T1-weighted MRI using Bridge Burner algorithm. J Magn Reson Imaging (2008) 1.41
Optimizing the efficiency of high-field multivoxel spectroscopic imaging by multiplexing in space and time. Magn Reson Med (2006) 1.35
Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol (2000) 1.34
Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann Neurol (2007) 1.33
A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. J Magn Reson B (1995) 1.33
The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child (2004) 1.32
N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology (2008) 1.31
Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell (2011) 1.31
Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav (2007) 1.25
Metabolic maturation of the human brain from birth through adolescence: insights from in vivo magnetic resonance spectroscopy. Cereb Cortex (2012) 1.23
Neurospectroscopy: the past, present and future. Chem Rev (2010) 1.21
Integrated data acquisition and processing to determine metabolite contents, relaxation times, and macromolecule baseline in single examinations of individual subjects. Magn Reson Med (2005) 1.15
Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. Arch Neurol (2003) 1.13
Age dependence of regional proton metabolites T2 relaxation times in the human brain at 3 T. Magn Reson Med (2008) 1.13
Standardized whole brain mapping of tubers and subependymal nodules in tuberous sclerosis complex. J Child Neurol (2004) 1.10
Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci (1991) 1.08
The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed (2012) 1.02
Longitudinal inter- and intra-individual human brain metabolic quantification over 3 years with proton MR spectroscopy at 3 T. Magn Reson Med (2011) 0.97
Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol (2007) 0.95
Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex. Acta Neuropathol (2012) 0.94
3D multivoxel proton spectroscopy of human brain using a hybrid of 8th-order Hadamard encoding with 2D chemical shift imaging. Magn Reson Med (1998) 0.92
Surgical outcome in tuberous sclerosis complex: a multicenter survey. Epilepsia (2007) 0.92
Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol (2005) 0.90
The utility of tuberless models of tuberous sclerosis. Epilepsia (2007) 0.89
Diffusion weighted MR findings of brain involvement in tuberous sclerosis. Diagn Interv Radiol (2006) 0.86
Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study. Ann N Y Acad Sci (1991) 0.79
Distribution and conspicuity of intracranial abnormalities on MR imaging in adults with tuberous sclerosis complex: A comparison of sequences including ultrafast T2-weighted images. Epilepsia (2009) 0.77
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med (2010) 4.24
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol (2004) 3.56
Oral tolerance. Immunol Rev (2005) 3.48
Anterior temporal lobectomy with amygdalohippocampectomy for mesial temporal sclerosis: predictors of long-term seizure control. J Neurosurg (2013) 3.29
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 3.00
Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol (2002) 2.94
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2008) 2.83
Diffuse axonal injury in mild traumatic brain injury: a diffusion tensor imaging study. J Neurosurg (2005) 2.78
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
The human K-complex represents an isolated cortical down-state. Science (2009) 2.54
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci U S A (2010) 2.41
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology (2008) 2.34
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov (2008) 2.30
Cannabinoids in the Treatment of Epilepsy. N Engl J Med (2015) 2.27
Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology (2006) 2.22
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Finite element analysis applied to 3-T MR imaging of proximal femur microarchitecture: lower bone strength in patients with fragility fractures compared with control subjects. Radiology (2014) 2.15
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (2010) 2.10
Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol (2007) 2.02
Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. AJNR Am J Neuroradiol (2002) 2.02
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol (2009) 2.00
Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging (2010) 1.96
Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.94
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology (2013) 1.86
Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic. Pediatrics (2008) 1.85
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.80
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol (2004) 1.78
Evaluation of bowel distention and bowel wall appearance by using neutral oral contrast agent for multi-detector row CT. Radiology (2005) 1.78
Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci (2003) 1.77
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol (2003) 1.75
Small pulmonary nodules: volume measurement at chest CT--phantom study. Radiology (2003) 1.73
IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol (2006) 1.72
Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology (2004) 1.72
Age-related non-Gaussian diffusion patterns in the prefrontal brain. J Magn Reson Imaging (2008) 1.72
Free-breathing radial 3D fat-suppressed T1-weighted gradient echo sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol (2011) 1.72
Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging (2010) 1.70
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Short-term DTI predictors of cognitive dysfunction in mild traumatic brain injury. Brain Inj (2008) 1.68
Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis. Radiology (2011) 1.66
What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol (2007) 1.64
Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 1.63
Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology (2012) 1.62
Heterogeneous neuronal firing patterns during interictal epileptiform discharges in the human cortex. Brain (2010) 1.62
A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev (2006) 1.62
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Health-related quality of life over time since resective epilepsy surgery. Ann Neurol (2007) 1.59
Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol (2003) 1.59
TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol (2006) 1.58
Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol (2012) 1.58
Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging (2002) 1.57
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol (2010) 1.56
Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol (2005) 1.56
Thalamus and cognitive impairment in mild traumatic brain injury: a diffusional kurtosis imaging study. J Neurotrauma (2011) 1.56
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Race/ethnicity, sex, and socioeconomic status as predictors of outcome after surgery for temporal lobe epilepsy. Arch Neurol (2006) 1.55
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery (2006) 1.54
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci (2005) 1.54
Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 1.52
Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol (2004) 1.52
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med (2005) 1.50
Free-breathing contrast-enhanced multiphase MRI of the liver using a combination of compressed sensing, parallel imaging, and golden-angle radial sampling. Invest Radiol (2013) 1.49
Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 1.48
Selective emotional detachment from family after right temporal lobectomy. Epilepsy Behav (2003) 1.47
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Impaired consciousness in temporal lobe seizures: role of cortical slow activity. Brain (2010) 1.44
Sex-specific normalized reference values of heart and great vessel dimensions in cardiac CT angiography. AJR Am J Roentgenol (2011) 1.43
Slow cortical dynamics and the accumulation of information over long timescales. Neuron (2012) 1.42
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42